Hologic, Inc. (NASDAQ:HOLX) Receives $78.42 Consensus Target Price from Brokerages

Shares of Hologic, Inc. (NASDAQ:HOLX) have earned a consensus rating of “Hold” from the fifteen ratings firms that are covering the stock, Marketbeat Ratings reports. Thirteen investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $78.4167.

Several equities analysts have recently commented on the company. Morgan Stanley increased their price objective on Hologic from $69.00 to $76.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 11th. Evercore cut shares of Hologic from an “outperform” rating to an “in-line” rating and reduced their price target for the company from $79.00 to $78.00 in a research report on Monday, January 5th. Argus downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, January 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of Hologic in a research note on Tuesday, November 4th. Finally, BNP Paribas Exane lowered shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price on the stock. in a report on Friday, November 21st.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $75.23 on Friday. The company’s fifty day moving average price is $74.95 and its 200-day moving average price is $72.06. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.04 and a quick ratio of 3.32. The firm has a market capitalization of $16.79 billion, a price-to-earnings ratio of 31.35, a PEG ratio of 2.25 and a beta of 0.72. Hologic has a one year low of $51.90 and a one year high of $75.49.

Hologic (NASDAQ:HOLX) last announced its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.09 by ($0.05). Hologic had a return on equity of 19.58% and a net margin of 13.18%.The company had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter last year, the firm posted $0.87 earnings per share. The firm’s revenue was up 2.5% on a year-over-year basis. On average, equities research analysts anticipate that Hologic will post 4.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Hologic

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Winnow Wealth LLC purchased a new position in Hologic in the 3rd quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd boosted its stake in shares of Hologic by 193.6% during the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 273 shares during the period. Root Financial Partners LLC bought a new position in shares of Hologic in the third quarter worth approximately $27,000. Harbor Capital Advisors Inc. purchased a new position in shares of Hologic in the fourth quarter worth $27,000. Finally, SJS Investment Consulting Inc. raised its holdings in Hologic by 341.5% during the 3rd quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 362 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.